COO Earnings Date: Dec 3, 2026 (Estimated) — The Cooper Companies, Inc.
NASDAQ · Healthcare · Medical Instruments & Supplies
Updated
When is COO's next earnings date?
The Cooper Companies, Inc. (COO) is expected to report Q4 2026 earnings on Thursday, December 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.07 on revenue of $1.07B.
How did COO do in its last earnings report?
In its most recent report on Sep 9, 2026 (Q3 2026), The Cooper Companies, Inc. posted EPS of $1.15 versus the $1.12 estimate, a beat of 2.7%. Revenue was $1.07B against a $1.10B estimate. The stock's 1-day post-earnings move was -14.7%.
How much does COO stock move after earnings?
COO beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.6% (up or down) in the day after earnings.
About The Cooper Companies, Inc.
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-09 | Q3 2026 | 1.12 | 1.15 | +2.68% | $1.07B | ✅ Beat | -14.67% | -13.97% | -14.46% |
| 2026-06-04 | Q2 2026 | 1.10 | 1.21 | +10.00% | $1.08B | ✅ Beat | +8.58% | +8.85% | +15.91% |
| 2026-03-05 | Q1 2026 | 1.03 | 1.10 | +6.80% | $1.02B | ✅ Beat | -4.55% | -10.82% | -12.36% |
| 2025-12-04 | Q4 2025 | 1.11 | 1.15 | +3.60% | $1.06B | ✅ Beat | +5.67% | +6.59% | +9.46% |
| 2025-08-27 | Q3 2025 | 1.07 | 1.10 | +2.80% | $1.06B | ✅ Beat | -12.85% | -8.24% | -8.85% |
| 2025-03-06 | Q1 2025 | 0.91 | 0.92 | +1.10% | $964.7M | ✅ Beat | -6.57% | -14.56% | -18.92% |
| 2024-12-05 | Q4 2024 | 1.00 | 1.04 | +4.00% | $1.02B | ✅ Beat | -4.39% | -6.31% | -10.21% |
| 2024-08-28 | Q3 2024 | 0.91 | 0.96 | +5.49% | $1.00B | ✅ Beat | +11.84% | +12.65% | +16.12% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $1.07B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Coopervision | 67.2% | $717.0M | -0.2% | $646.1M | $669.6M | $718.4M | $709.7M |
| Coopersurgical | 32.8% | $349.2M | +2.1% | $318.6M | $332.7M | $341.9M | $355.4M |
By region
Q3 FY26 · $1.07B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 48.7% | $519.5M | +0.6% | $496.4M | $515.2M | $516.2M | $1.21B |
| Europe | 33.5% | $357.5M | +4.2% | $287.5M | $291.9M | $343.1M | $1.46B |
| Rest Of World, Excluding United States And Europe | 17.7% | $189.2M | -5.9% | $180.8M | $195.2M | $201.0M | $208.2M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.